Oncomine Comprehensive myeloid/ Leukemia Panel (DNA + RNA fusions)

Description

The Oncomine Comprehensive Myeloid/Leukemia Panel (DNA + RNA Fusions) is a cutting-edge, next-generation sequencing (NGS) solution designed to deliver a complete genomic profile of myeloid malignancies and leukemias from a single, streamlined assay. Developed for clinical and translational research, this all-in-one panel enables simultaneous detection of key DNA mutations and RNA fusion transcripts, providing a powerful tool for comprehensive molecular characterization of hematologic cancers.

This panel targets over 40 genes frequently mutated in myeloid disorders, including AML, MDS, MPN, and CML, covering critical single nucleotide variants (SNVs), insertions/deletions (indels), and copy number variations (CNVs). In addition, it detects over 30 clinically relevant gene fusions and splice variants from RNA, including BCR-ABL1, PML-RARA, and KMT2A rearrangements, offering unparalleled insight into the complex genomic landscape of leukemia.

Key Features:

– Dual DNA and RNA analysis in a single workflow, reducing sample input and turnaround time
– Comprehensive coverage of key myeloid and leukemia-associated genes and fusions
– Optimized for low-input, degraded, or limited bone marrow and peripheral blood samples
– Compatible with Ion Torrent NGS platforms for fast, accurate results
– Streamlined bioinformatics with integrated variant annotation and fusion detection

Benefits:

– Enables precise molecular profiling to support diagnosis, risk stratification, and treatment selection
– Reduces the need for multiple sequential tests, conserving precious samples and accelerating time to results
– Facilitates identification of actionable mutations and emerging biomarkers for targeted therapy and clinical trial enrollment
– Supports research into disease mechanisms, clonal evolution, and resistance pathways

Value Proposition:

The Oncomine Comprehensive Myeloid/Leukemia Panel empowers laboratories and researchers with a robust, efficient, and clinically relevant solution for hematologic cancer profiling. By integrating DNA and RNA analysis into a single assay, it delivers a holistic view of the genomic alterations driving disease, enabling more informed decision-making and advancing precision medicine in hematology-oncology.